一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括Online Adaptive Radiotherapy With Sequential Boost；Conventional Non-Adaptive IMRT；Capecitabine；CAPEOX；Total Mesorectal Excision，当前状态为研究进行中，已停止招募。登记地点显示中国济南有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Online Adaptive Radiotherapy With Sequential Boost；Conventional Non-Adaptive IMRT；Capecitabine；CAPEOX；Total Mesorectal Excision · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute · 济南
公开的入选条件
- 1. Age 18 years or older.
- 2. ECOG performance status of 0 or 1.
- 3. Histologically confirmed rectal adenocarcinoma.
- 4. Primary tumor located within 10 cm of the anal verge by pelvic MRI and/or rigid sigmoidoscopy.
- 5. Clinically involved regional lymph nodes (cN1-2) according to the AJCC 8th edition.
- 6. At least one additional high-risk feature: cT4 disease, cN2 disease, extramural vascular invasion, mesorectal fascia involvement, lateral pelvic lymph-node involvement, tumor deposits, or low rectal cancer (≤5 cm from the anal verge).
- 7. Baseline locoregional staging with contrast-enhanced pelvic MRI and chest/abdominal imaging excluding distant metastases.
- 8. Treatment-naïve with respect to systemic therapy and pelvic radiotherapy for the index rectal cancer and suitable for total mesorectal excision.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06246344；登记信息更新于 2026-09-15。